Dashboard

BioMarin Pharmaceutical, Inc. (BMRN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

About

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

CEO

Jean-Jacques Bienaimé

Employees

3,001

Industry

Endocrinology and Metabolism Biopharmaceuticals

Sector

Healthcare

Headquarters

San Rafael

Exchange

NASDAQ

Summary Stats

Market Cap

17.1B

Revenue

2.1B

Net Income

142M

EPS

$0.75

Price-to-Earnings

122.07

Price-to-Book

3.71

Debt-to-Equity

0.39

News

Analyst Ratings

Price targets projected by 22 analysts

High

$187.00

Average

$108.73

Low

$80.00

Ratings calculated by 25 analysts

Buy

15

Hold

10

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q4 2022

Last Earnings

Above by $0.07

Actual

$0.00 +100.0%

Consensus

-0.07

Report Date

Year Ago

-0.32

Year Ago Change %

Up 100%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites